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REVIEW ARTICLE
Effects of hyperthermia in neutralising mechanisms of drug resistance in
non-muscle-invasive bladder cancer
Antoine G. van der Heijdena and Mark W. Dewhirstb
aDepartment of Urology, Radboud University Medical Centre, Nijmegen, the Netherlands; bRadiation Oncology, Duke University, Durham,
North Carolina, USA
ABSTRACT
Non-muscle-invasive bladder cancer is a challenging disease, even given its superficial nature. It is prone
to multiple recurrences and progression to muscle-invasive cancer. These features of this disease con-
tribute significantly to reduced quality of life as well as creating significant morbidity and even mortal-
ity. Randomised trials demonstrate that when hyperthermia is added to conventional mitomycin-C
treatment that local control rates and progression-free survival are substantially improved. In this review
we consider how hyperthermia can exert such beneficial effects. Some of the mechanisms presented
are theoretical, while others are facts. It is hoped that this review will contribute rationale for further
examination of mechanisms, because an understanding of such mechanisms may lead to even better
chemotherapeutic approaches, as well as potential biomarkers for predicting and monitoring treatment
success.
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Introduction
A series of previous studies in bladder cancer have shown
that the non-muscle-invasive bladder cancer (NMIBC) recur-
rence rate is substantially reduced following radiofrequency-
induced hyperthermia plus mitomycin-C (MMC), compared
with ‘conventional’ intravesical MMC instillation [1].
Furthermore, the progression rate is low, even in patients pre-
senting with carcinoma in situ (CIS), grade 3 (G3) tumours
and patients failing BCG prior to radiofrequency-induced
chemo-hyperthermia (RF-CH) treatment [2]. There are multiple
potential reasons for the enhanced effects of this combin-
ation therapy. In this review we consider effects of hyperther-
mia on drug transport and on cell-killing efficiency. We
believe that both play an important role in the success of this
therapeutic combination.
Drug transport barriers
There are multiple barriers to effective delivery of drugs to
cancers at cytotoxic concentrations. First, there are substan-
tial barriers to deliver adequate concentrations of drug
throughout the tumour volume. Second, cells have delivery
barriers that must be circumvented. Drug has to be taken
up by the cell in sufficient quantity to hit the intracellular
target in order to be cytotoxic. Mechanisms of cellular drug
resistance have been identified by many investigators and
will be discussed.
Barriers to transport of drugs from intravesical
administration
The challenges of drug delivery following intravenous admin-
istration have been discussed in excellent reviews [3,4]; but
the basic concepts have not been discussed previously with
reference to treatment of NMIBC, where drugs are typically
administered intravesically. In this review we examine those
features of drug transport from intravesical administration
that are influenced by hyperthermia. We will focus mainly on
discussion of MMC because it is a standard of care. However,
the principles discussed are appropriate to any small mol-
ecule drug. In the discussion we will briefly examine issues
related to intravenous drug administration, which is not cur-
rently used for NMIBC. Intravenous drug could be used if a
method could be developed that could reduce systemic tox-
icity while maintaining cytotoxic drug levels in the bladder.
We discuss thermosensitive liposomes as a platform through
which this goal could theoretically be achieved.
Sites of growth of NMIBC and rationale for standards of
care
NMIBC is located in the mucosa and can extend into the sub-
mucosa, but has not penetrated into the muscle layer. There
is low probability for regional or distant metastasis with this
presentation; therefore, it is considered a localised disease.
Intravesical chemotherapy is used for NMIBC, since the
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highest concentration of drug will be delivered directly to the
site of tumour growth. In addition, one would not want to
subject a patient who has local disease to the toxicities asso-
ciated with systemically administered drug. However, there
are substantial hurdles to achieving uniform cytotoxic drug
delivery with NMIBC. Here we discuss the barriers and then
how hyperthermia can improve drug delivery.
The standard of care for newly diagnosed NMIBC is trans-
urethral resection of the tumour, followed by intravesical
chemotherapy in low or intermediate risk, and immunother-
apy with bacillus Calmette-Guerin (BCG) in intermediate- or
high-risk NMIBC patients [5]. Although these therapies are ini-
tially effective, the 5-year recurrence rate is up to 80%,
depending on the stage and grade of the tumour. The conse-
quences of these recurrences are twofold. First, recurrences
may require many resections. Eventually, this will lead to
inability of the bladder to retain acceptable volumes of urine
because the elasticity becomes compromised. This may
require complete removal of the bladder, known as a cystec-
tomy, because of functional problems. Cystectomy is associ-
ated with substantial morbidity. Even in experienced centres
the 30 and 90 days perioperative mortality rate is respectively
around 2 and 7% [6]. Second, approximately 15% of patients
with high grade NMIBC will progress to muscle-invasive can-
cer, which also has a much worse prognosis compared to de
novo muscle-invasive disease [7,8]. Thus, there is strong
rationale to develop therapies that can lower recurrences and
prevent progression to muscle-invasive disease.
One might assume that treatment efficacy would be maxi-
mised by using intravesical chemotherapy for NMIBC, since
the drug will be in high concentration immediately adjacent
to the mucosal surface. However, there are impediments to
efficient drug delivery by intravesical means.
Glycosaminoglycans present a barrier to drug penetration
The inner lining of the bladder is covered by a thick layer of
glycosaminoglycan (GAG), which is an effective barrier that
limits passage of drugs to the tumour bladder cell surface
[9,10]. In order to increase drug penetration across the GAG
layer, one must either remove the GAG or enhance drug
transport across it. A number of methods have been used to
temporarily disrupt the GAG layer, as a means to enhance
drug delivery. Examples include instillation of mild detergents
and dimethylsufoxide (DMSO) [9]. Additionally, drugs that
inhibit GAG synthesis have been used to reduce the thickness
of the layer [11]. Alternatively, glycosaminoglycan drug car-
riers have been shown to be taken up into GAG layers,
increasing penetration of drug into tumour interstitium
[12,13]. GAG has also been considered a barrier to effective
therapy with the immunotherapeutic drug BCG [14]. Although
these methods have resulted in improvements in antitumour
effects of drugs in pre-clinical models, none have been
approved for use in conjunction with intravesical
chemotherapy.
Urothelium is the next layer of defence against drug
penetration
The urothelium is composed of three types of cells: basal,
intermediate and umbrella cells (Figure 1). The umbrella cells
are very specialised to add another tight barrier to prevent
urine and bacteria from passing from the bladder into adja-
cent tissues [15]. Tight protein-based junctions form between
adjacent cells, which contribute to the impenetrability of this
layer [16]. The lipid composition is comprised of cholesterol,
phosphatidyl choline, phosphatidyl ethanolamine, and cere-
broside. This composition makes the layer very water imper-
meable. To be able to deliver drugs to NMIBC, one must
penetrate this impermeable layer.
Drug must penetrate through the mucosal surface to reach
all tumour cells
MMC penetration across the bladder wall has been measured
following intravesical chemotherapy in human patients [17].
Concentrations dropped from 120 lg/mL in the urine, to
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Figure 1. Structure of bladder wall. This wall is very impermeable to water. The umbrella cells contain a high percentage of highly hydrophobic lipids in addition to
having very tight junctions between cells. Drugs must traverse through the glycosaminoglycan layer, three layers of cells, the basal lamina and underlying stroma to
reach to the depth of tumour cells. NMIBC cells do not penetrate into the first muscle layer. It has been reported that hyperthermia can damage this mucosal layer,
thereby increasing drug penetrability.
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5.6 lg/mL in the urothelium and 0.9 lg/mL in the muscle
layer. Thus, there is a 20-fold drop in drug concentration just
to the urothelium and a 100-fold drop to the muscularis. The
distance over which the drug concentration in the bladder
wall drops by 50% is 500lm. The unfolded mucosal cell layer
is 200lm thick [17]. However, if the bladder is partially col-
lapsed the drug may have to penetrate through several
folded mucosal layers to reach all cells, as described next.
Folded mucosal layer and penetration depth
In the constricted state, the bladder wall is folded on itself,
much like a collapsed hot air balloon (Figure 2) [15]. When
the bladder is fully stretched, these folds disappear. At this
point, the depth that drug must diffuse to be effective is min-
imal. When drug is instilled into the bladder, the volume is
much smaller than the bladder capacity. This is done to allow
for the bladder to fill during drug administration. A typical
treatment lasts 1–2 h, during which time, the patient will pro-
duce urine. Whether or not the bladder reaches full capacity
is unknown, but it is safe to say that for much of the time
that drug is present, the folded mucosal layers present a bar-
rier to effective diffusion.
Positive effects of hyperthermia on drug transport
Hyperthermia may exert beneficial effects related to the deliv-
ery limitations listed above. Some of these mechanisms will
work directly on tumour cells as well as uroepithelial cells. It
will become apparent that hyperthermia exerts beneficial
effects to enhance drug transport across multiple barriers that
emanate from intravesical therapy.
Effects on GAG and urothelial layers
Hyperthermia has been shown to transiently damage the uro-
thelium, which can increase the rate of drug uptake into the
bladder wall [18]. This results in increased drug absorption
when radiofrequency-induced hyperthermia is applied [19].
This increase is even more pronounced in patients with unre-
sected tumours.
Potential mechanisms for enhancement of drug transport
across urothelium
Cytoskeleton Hyperthermia has been reported to cause tran-
sient changes in the cytoskeleton of cells; this is largely attrib-
uted to the disassembly microtubules, microfilaments and
actin fibres [20]. The cytoskeleton is known to be involved in
maintenance of cell shape. If it collapses, this may weaken
the tight junctions between the uroepithelial layers, thereby
increasing permeability. We reported previously that hyper-
thermia increases microvascular permeability, opening up
pores between endothelial cells of 100–400 microns in size
[21]. Similar effects may occur with the urothelium. It is
important to know that these cytoskeletal changes are transi-
ent and recover as cells induce the production of heat shock
proteins in response to thermal stress [20].
Hyperthermia Enhances drug diffusion
The delivery of a small molecule through a tissue layer is
dependent upon the diffusion coefficient. Diffusion coeffi-
cients are temperature dependent. According to the Stokes-
Einstein equation, the diffusion coefficient increases by 14%
when temperature increases from 37 to 43 C, with this rise in
temperature the hydraulic conductivity is also increased by
12% [22]. The increase in hydraulic conductivity is the result
of enhanced permeability in the interstitium and reduced
fluid viscosity. Hyperthermia (42 C) has been shown to
decrease urine viscosity by approximately 10%, as compared
with 37 C [23]. This combination of effects could contribute
to increased drug penetration into the bladder wall.
Hyperthermia affects tissue structure The effects of hyper-
thermia on cell density and shape may also contribute to
enhanced drug transport. It has been reported that increased
drug uptake into tumours can occur if efforts are made to
reduce tumour cell density [3]. There are several reports indi-
cating that hyperthermia can increase efficacy of a variety of
chemotherapeutic agents. Apoptosis is a common mode of
death following such treatments [24]. Ware et al. observed a
decrease of 15% in cell volume 24 hours after radiofrequency
(RF) treatment [25]. They concluded that decreases in
individual cell area do play an important role in alteration of
cell–cell junctions. There was also a loss of cell adhesion.
Furthermore, radiofrequency alters the surface roughness of
malignant cells. This change will influence the interactions
between chemotherapy and the cell membrane. Further,
hyperthermia increased tunnelling nanotube formation, which
results in more cell-to-cell interactions. Tunnelling nanotube
formation has been shown to enhance particle trafficking in
Figure 2. Folded mucosal surface of unfilled rabbit bladder. In this state there
are multiple mucosal layers folded on top of each other. The multiple layers will
restrict access of drug to all tumour cell locations. Intravesical therapy involves
instilling 40mL of MMC-containing solution. This volume does not stretch the
bladder to its full capacity. Over time, the bladder will fill, which will stretch the
bladder, reducing the size and number of folds. It has been reported that intra-
vesical hyperthermia increases urine production. In a clinical trial involving intra-
vesical MMC and radiofrequency hyperthermia, 82–95mL of urine was recovered
from unheated control patients versus 130mL was recovered from patients who
received the hyperthermia treatment [19]. There is a trade-off regarding the
value of bladder filling. On the one hand, stretching of the wall will reduce the
folded layers, making the mucosal surface more exposed to drug. On the other
hand, the filling dilutes the drug.
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cancer cells. These observations by Ware were performed in
circumstances where temperature was controlled to <39 C. It
is unclear whether similar effects would be observed if thera-
peutic temperatures were induced with RF. Induction of a
wave of apoptosis after thermochemotherapy could reduce
tumour cell packing density, thereby enabling more effective
administration of a second drug [3]. To our knowledge, this
therapeutic strategy has not been attempted for treatment of
NMIBC. Similarly, use of agents that can modify the density of
the extracellular matrix can also improve drug penetration [3].
To our knowledge, however, there have not been any reports
indicating whether hyperthermia changes extracellular matrix
to improve drug transport.
Potential negative effects of hyperthermia on drug
transport
Tissue oedema
Transient oedema was observed in sheep bladder tissues after
hyperthermia [18]. The diffusion distance of a small molecule
is proportional to L2/D, where L is the distance and D is the
diffusion coefficient. Bladder oedema could increase the thick-
ness of the bladder wall, which could reduce drug delivery by
increasing the distance over which drug must diffuse to reach
target tumour cells. Oedema would also reduce the local
drug concentration, which could reduce the drug concentra-
tion gradient. These two effects could reduce drug transport
across the bladder wall. On the other hand, the diffusion of
drug can increase because tissue density is decreased in the
presence of oedema. This would tend to increase the diffu-
sion distance. It is difficult to predict the net effect of hyper-
thermia on drug diffusion, given these offsetting forces.
Urine production during heating dilutes drug
concentration in bladder
Dilution of drug by urine can reduce the exposure of the
bladder wall to drug. In a human clinical trial, urine concen-
trations of MMC were measured during and after treatment.
Patients were treated with and without intravesical hyperther-
mia with a microwave antenna. Patients who received hyper-
thermia produced more urine, thereby resulting in more
dilution of drug than the control patients who were not
heated. For example, at an intravesical dose of 40mg the
urine concentration dropped by fourfold in the heated group,
compared with 2.2-fold in the control group [19].
Increased perfusion may remove drug from target
volume
Even though NMIBC is superficial, these tumours can be vas-
cularised [26]. There is additional vasculature in the muscle
layer, deep in relation to the position of the tumour.
Hyperthermia at 43 C for up to 2 h increases skeletal muscle
perfusion of rats by 3.5- to sixfold [27]. Similar effects were
observed in canine thigh muscle in response to thermal stress
[28]. The tissue response to thermal stress follows a biphasic
curve, where perfusion increases by approximately twofold
between 37 and 42 C. Above 42 C, perfusion increases by
approximately a factor of 3 for every 1 C rise in temperature
[28]. Multiple mechanisms have been postulated to be
involved in the regulation of perfusion upon thermal stress.
These include enhanced release of vasoactive substances,
such as bradykinin and prostacyclin. In addition, enhanced
NO production by vascular endothelium could contribute [28].
The muscularis of the bladder is composed of smooth muscle,
so one has to consider whether there is precedent for hyper-
thermia having a direct effect on perfusion of this organ.
Activation of TRP (transient receptor potential) channels may
be involved in regulating smooth muscle vasodilation upon
heat stress [29,30]. Perfusion in tumours can increase as well
by as much as 2-fold [27]. The increase in perfusion in both
tumour and muscle of the bladder wall could enhance drug
removal from the tumour, where it could be redistributed sys-
temically. Paroni et al. reported that systemic levels of MMC
were increased following intravesical administration in
patients who received local heating of the bladder [19]. On
the one hand, this observation is consistent with the concept
that systemic removal of drug is increased with local hyper-
thermia delivered to the bladder. On the other hand, the fact
that there is an increase in systemic levels of drug means
that the drug was penetrating deep enough to be picked up
by the blood vessels. Presumably, this is indirect evidence for
greater tumour cell exposure to drug as well, since the drug
would have to pass through multiple cell layers to reach the
deeper vasculature. The systemic levels of drug achieved with
hyperthermia were below those that are known to cause nor-
mal tissue toxicity.
Theoretically, exposure of tumour cells to drug could be
increased if hyperthermia causes vascular damage in tumours.
Such damage would reduce systemic uptake of drug. In early
studies there was the suggestion that the vasculature of
tumours is more thermally sensitive than that of normal tis-
sue, with thresholds of thermal damage in the range of
42–43 C for 1 h exposure [27]. Most of those data were based
on observations in rodents. More recent studies have indi-
cated that the vasculature of human/canine tumours is more
resilient and that vascular shut down does not occur below
temperatures of 44 C for 1 h. For example, in companion
canine soft tissue sarcomas, intratumoural temperatures in
the range of 40–43 C resulted in increases in tumour perfu-
sion and oxygenation at 24 h post-hyperthermia treatment
[31]. In contrast, temperatures >44 C resulted in reduced
perfusion and oxygenation, most likely as a result of vascular
damage. Similar results were observed in women with locally
advanced breast cancer who were treated with a combination
of hyperthermia, radiotherapy and chemotherapy. Further,
reoxygenation was associated with better clinical response in
the locally advanced breast cancer study [32]. The prescribed
temperature range for bladder heating is in the range of
42–43 C [33,34]. Thus it is unlikely that vascular damage to
the tumour or normal tissue vasculature is a consequence. If
vascular damage did occur, the consequence could easily
result in less drug uptake by the tumour. This could occur
because such damage would not maintain the concentration
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gradient of drug across the tumour – should this occur,
Fickian diffusion could be reduced.
Hyperthermia increases drug uptake by, and
cytotoxicity of, tumour cells
Hyperthermia has been reported to increase cellular uptake
of some drugs; this increase has been considered one of the
factors that leads to enhanced antitumour effects. Cisplatin,
MMC, gemcitabine, doxorubicin and epirubicin, are all used in
intravesicle treatment of bladder cancer. We will discuss the
effects of hyperthermia on cellular transport of these drugs in
more detail.
The permeability of lipid bilayers is affected by the order
of acyl chains of phospholipids. Increasing temperature
reduces the order of the acyl chains, thereby increasing per-
meability. Increases in membrane fluidity have been associ-
ated with increases in drug uptake by cells, including
doxorubicin [35], and cisplatin [36]. However, the effects of
hyperthermia on cell membrane fluidity are not the entire
explanation for enhanced uptake for all drugs.
Hyperthermia inhibits DNA damage repair. The most
important lethal target is the double strand break, which is
repaired by two mechanisms: non-homologous end joining
and homologous recombination. Both of these mechanisms
of repair are inhibited by hyperthermia [37]. Important ther-
mal targets include DNA polymerases and poly(ADP-ribose)-
polymerase-1 (PARP) [38,39]. PARP functions to direct DNA
repair enzymes to the location of strand breaks. Thermal
inhibition of BRCA2, an enzyme responsible for initiation of
DNA repair, combined with inhibition of PARP is synthetically
lethal to target cells. Hyperthermia has also been reported to
inhibit recombination repair of stalled DNA replication forks,
which are the primary target lesion of gemcitabine [40].
Cisplatin
Alberts was one of the first investigators to report that hyper-
thermia (42 C) increased cytotoxicity of cisplatin, in vivo,
using a mouse leukaemia line [41]. Using radiolabelled cis-
platin, he demonstrated that hyperthermia increased cellular
uptake of cisplatin. Meyn et al. reported that hyperthermia
(43 C) of CHO cells increased the extent of lethal DNA cross-
links created by cisplatin [42]. The dose modifying factor,
which is the ratio of drug doses to achieve an equal level of
cytotoxicity at 37 C versus 43 C, was nearly a factor of 6.
They hypothesised that the increase in crosslinks could be a
result of inhibition of DNA damage repair, but the rate of dis-
appearance of crosslinks was the same for both temperatures.
They concluded that the increase in cytotoxicity of cisplatin
by hyperthermia was most likely caused by an increase in
drug uptake. Los et al., demonstrated that regional hyperther-
mia (41 C) increased drug uptake by over fourfold, increased
DNA crosslinking by 2.5-fold and increased in vivo efficacy of
cisplatin, using a rat colon carcinoma line [43]. Los also
reported that the threshold for enhancement of cisplatin
uptake by hyperthermia was 38.5 C [44]. Using isolated DNA,
they were able to show that the rate of cisplatin binding to
DNA was not temperature dependent. Thus, it is reasonable
to conclude that the enhancement in cytotoxicity caused by
hyperthermia is a result of increased cellular uptake, leading
to an increase in DNA crosslinks. It has been recently reported
that the mechanism of enhanced cisplatin uptake is related
to the function of the copper transporter, CTR1. Hyperthermia
increases the extent of CTR1 multimerisation, which creates a
membrane pore to facilitate cisplatin uptake [45]. Wallner and
Li demonstrated that the greatest effectiveness of cisplatin
with hyperthermia occurs when the two are given simultan-
eously, with a hyperthermia treatment period of 1 h [46].
Longer heating times were less effective. This observation fits
well with the expected use of cisplatin with hyperthermia,
since the drug would be instilled into the bladder and hyper-
thermia could commence quickly after instillation.
Mitomycin C
There are several references related to the combination of
hyperthermia with MMC, dating back to the early 1980s
[47–52]. Wallner et al. examined the effects of hyperthermia
on cytotoxicity of MMC in drug-sensitive and drug-resistant
Chinese hamster ovary (CHO) cell lines [53]. Dose-modifying
factors for 42 and 43 C heating with MMC ranged from
1.3–2.0 and 2.6–3.8, respectively. The magnitude of the dose-
modifying factor was independent of whether the cells were
drug sensitive or drug resistant. Hyperthermia (43.5 C)
increased cellular uptake of MMC by 78% versus 27% for
drug-sensitive versus drug-resistant cell lines. Like cisplatin,
simultaneous administration of drug and hyperthermia was
the most efficacious.
Teicher et al. examined the effects of hyperthermia (41, 42
and 43 C) on cytotoxicity of MMC, under aerobic and hypoxic
conditions [49]. Although they did not measure drug uptake,
they found that the rate of formation of active drug increased
remarkably when hyperthermia was added to drug. Further,
they demonstrated that the thermal enhancement of MMC
killing was greater in hypoxic cells than in aerobic cells.
Considering that bladder cancer can be hypoxic, this provides
very strong rationale for using MMC in combination with
hyperthermia [54].
Gemcitabine
We were able to identify one paper in which intratumoural
gemcitabine concentrations were measured after hyperther-
mia treatment (42 C). These authors did not observe any
increase in gemcitabine uptake with hyperthermia [55]. We
were unable to identify any in vitro studies that examined the
question of whether hyperthermia augmented drug uptake.
Hyperthermia (43 C) has been shown to enhance the
cytotoxicity of gemcitabine, however. In one study, two pan-
creatic cell lines were assessed for cell viability by the WST-8
assay, which reports on cell mass after treatment [56]. This
assay reflects the balance between cell death and cell prolif-
eration. Reduction in WST-8 signal occurred in two scenarios:
when heat was administered 24 h prior to drug, or when the
two treatments were given simultaneously. The enhancement
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in cell killing was associated with thermal inhibition of NFŒB
activation by tumour cells.
Vertrees et al. examined the combination of gemcitabine
and hyperthermia (temperatures between 40 and 44 C for
periods ranging from 60 to 180min) using a human non-
small-cell lung cancer line [57] .The optimal sequence was as
discussed above, where hyperthermia was administered 24 h
prior to drug treatment. The optimal temperature was found
to be 43 C. Using isobologram analysis of in vitro survival
data, they demonstrated that this combination led to syner-
gistic killing. The mechanism of killing appeared to be related
to activation of apoptosis. Interestingly, however, they were
able to demonstrate a significant prolongation of tumour
regrowth when tumour-bearing animals were exposed to
40 C for 1 h, 24 h prior to gemcitabine treatment. Haveman
also reported that a 24-h delay between hyperthermia treat-
ment and gemcitabine yielded the greatest level of cell killing
as assessed by clonogenic assay [58].
Mohamed et al. reported that administration of gemcita-
bine immediately prior to heating at 41.5 C led to enhanced
antitumour effect [59]. Close examination of these data, how-
ever, shows that the enhancement was quite small in
magnitude.
In contrast to most of the results reported above suggest-
ing that a 24-h period between heating and administration of
gemcitabine was required for optimal enhanced cytotoxicity,
Raoof et al. recently reported that enhanced antitumour
effect in a hepatoma tumour line was seen regardless of
whether gemcitabine was given 22 h after or immediately
after heating [40].
Given the recent results of Raoof et al., it would seem pru-
dent to conduct additional studies, using thermal conditions
seen with bladder heating, to determine whether heating
immediately prior to drug administration would yield positive
effects. Logistically, this would much easier to translate to the
clinic, than requiring a 24-h period between the two
treatments.
Doxorubicin
There are several reports in the literature demonstrating
that hyperthermia increases doxorubicin uptake and reten-
tion by cells. In some reports, hyperthermia enhanced
doxorubicin cytotoxicity. Further, hyperthermia facilitated
uptake into both drug-sensitive and drug-resistant tumour
cells. Key conceptual papers are discussed. Unlike cisplatin
and MMC, there is some controversy as to what the ideal
temperature would be to facilitate enhanced drug uptake
and cell killing.
Hahn was the first investigator to report that hyperthermia
increases doxorubicin uptake by tumour cells [60]. Using the
CHO cell line, they observed little enhancement of doxorubi-
cin cytotoxicity at 41 C, but substantial enhancement at
42 C. Using an in vivo, in vitro clonogenic assay of the EMT6
tumour grown in mice, they demonstrated that 43 C heating
yielded a dose-modifying factor for cell survival of nearly six.
Concomitantly, they observed a threefold increase in
fluorescence intensity of doxorubicin in 43 C heated cells,
compared with 37 C controls.
Bates and McKillop examined the effects of hyperthermia
(39–45 C) on doxorubicin cytotoxicity of drug-sensitive and
drug-resistant CHO cells [61]. Hyperthermia (43 C) enhanced
the rate of uptake of radiolabelled doxorubicin by approxi-
mately 80%. Enhancement of doxorubicin cytotoxicity of the
drug sensitive line was seen at temperatures >39 C (two- to
threefold increase in cell killing compared with 37 C), but the
greatest enhancements in cytotoxicity were seen at tempera-
tures of 42 C (relative increase in cell killing by factors of
10, 50 and 100 at T ¼ 42, 43 and 45 C, respectively). In con-
trast, hyperthermia administration, even up to temperatures
of 47 C, did not increase drug cytotoxicity of the drug-resist-
ant line.
Using an elegant confocal approach, Kawai et al., demon-
strated that 43 C hyperthermia increased the accumulation
of doxorubicin into the nuclei of both drug-sensitive and
drug-resistant oesophageal carcinoma cell lines [62]. The
enhancement in uptake was 4.3 and 7.2-fold for the drug-sen-
sitive and drug-resistant lines. Hyperthermia enhanced the
cytotoxicity of doxorubicin in both the wild-type and drug-
resistant cell lines. In fact, the enhancement of cytotoxicity
was equivalent between the two cell types in this study.
Epirubicin
We were unable to identify any papers that examined the
effects of hyperthermia on epirubicin drug uptake. The tox-
icity of epirubicin-treated cells under hyperthermic conditions
was examined in a paper that is described more fully below.
Hyperthermia inactivates membrane drug pumps and
intracellular detoxification mechanisms
Inactivation of detoxification mechanisms could increase
drug uptake by urothelium for transport to deeper tumour
cell layers. These same mechanisms will be important for
enhancing tumour cell killing as well. Such mechanisms
include ATP-binding cassette (ABC) drug pumps, such as p-
glycoprotein [63], and antioxidant mechanisms such as
glutathione [64,65].
Hyperthermia has been reported to inactivate multiple
drug detoxification mechanisms. From a phenomenological
point of view, Wallner et al. were among the first to report
that hyperthermia could at least partially reverse drug resist-
ance to MMC. They demonstrated that drug uptake was
increased by heat in wild-type and MMC-resistant CHO cells
[53]. The increases in drug uptake were associated with
enhanced cytotoxicity. It has also been reported that hyper-
thermia reduces cell membrane localisation of multidrug
resistance proteins, when combined with MMC [66]. If cellular
uptake of drug is increased as a result of inactivating pumps,
this will contribute to maintaining a drug concentration gradi-
ent in the tissue. Small molecules such as MMC diffuse
through tissue, driven by their concentration gradient [67].
Once the drug enters a cell, it no longer contributes to the
gradient.
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Glutathione is the primary intracellular modifier of oxida-
tive stress. It has been shown to play a role in reducing cyto-
toxicity of a variety of drugs, including MMC [68]. Laskowitz
et al. demonstrated that hyperthermia reduced intracellular
glutathione levels and that this was associated with enhanced
in vivo activity of melphalan against a drug-resistant rhabdo-
myosarcoma xenograft [69]. The reduction in glutathione lev-
els may in part be due to an increase in oxidative stress that
has been associated with hyperthermia treatment [70,71].
Rationale for intravenous drug administration in the
treatment of NMIBC
Intravenous drug administration has not been considered
clinically viable for NMIBC, because of the low probability that
patients that present with NMIBC would have spread of their
disease beyond the confines of the bladder wall. Under the
mantra of ’doing no harm‘, it is difficult to justify administer-
ing a toxic drug to such a population of patients, since such
drugs have substantial systemic toxicities. Furthermore it is
also important to realise that the drug dose administered in
the bladder is much higher than the dose that can be used
intravenously.
Theoretically, however, administration of systemic drug has
some merit, particularly considering the fact that NMIBC often
has a vascular supply. If one were able to administer a drug
systemically, but stimulate its action selectively in the bladder,
then systemic toxicities could be minimised. One such
approach might be to use a thermally sensitive drug carrier,
such as a liposome or other nanoparticle [72,73]. In this case,
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Figure 3. Cell survival curves using increasing concentrations EO9, the most potent drug in our preclinical study. Effect of 1 h hyperthermia (43 C) and EO9 treatment
(red line, triangle) on the growth of four human bladder cancer cell lines compared to cells treated 1 h with EO9 at 37 C (blue line, square).The dotted line indicates
the LD50 axis. The vertical axis represents the cell survival (scale 0–1) and the horizontal axis represents the concentration EO9 in lg/mL.
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hyperthermia could be used to stimulate enhanced drug
release in the bladder. Clinical trials with a doxorubicin-con-
taining thermosensitive liposome indicate that the systemic
toxicities are no higher or different than those of free drug,
when given at the maximally tolerated dose [74,75]. However,
local hyperthermia triggers intravascular drug release in the
heated zone. This mechanism enhances drug delivery to the
tumour many fold, increases drug diffusion distance from the
vasculature and enhances antitumour activity of several
drugs, including doxorubicin, cisplatin and gemcitabine
[76–80]. Because of the differential in systemic versus local
effects of these formulations, one could administer less than
the maximally tolerated dose and still enhance drug delivery
to the bladder tumour. However, this approach still has to be
considered experimental.
Summary regarding temperature dependence of drug
uptake and cytotoxicity
Since the target temperature for intravesical hyperthermia is
41–42 C, we will summarise the salient points about how
temperatures in this range can alter drug uptake and cytotox-
icity. For both cisplatin and MMC, heating in this temperature
range will increase drug uptake and enhance cell killing by
substantial amounts. The most efficient cell killing occurs if
the drugs and heat are given simultaneously.
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Figure 4. Cell survival curves using increasing concentrations MMC, the most often used intravesical chemotherapeutic drug. Effect of 1 h hyperthermia (43 C) and
MMC treatment (red line, triangle) on the growth of four human bladder cancer cell lines compared to cells treated 1 h with MMC at 37 C (blue line, square). The dot-
ted line indicates the LD50 axis. The vertical axis represents the cell survival (scale 0–1) and the horizontal axis represents the concentration MMC in lg/mL.
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The effects of hyperthermia on doxorubicin accumulation
and cytotoxicity are somewhat more complicated. The litera-
ture shows that minor enhancements in cell killing can be
seen at 41 C, but the enhancement is much greater at
>42 C. Therefore, when using doxorubicin it may be advised
to push intravesical temperatures to 42 C or even slightly
above.
Currently, one report indicates that hyperthermia does not
increase gemcitabine uptake; but there are several reports
showing that gemcitabine cytotoxicity is enhanced by hyper-
thermia. In most studies, the greatest enhancement occurs if
the drug is given 24 h after heating. However, recent data
suggest that similar antitumour effects can be seen when
gemicitabine is given immediately after hyperthermia.
Direct comparison of hyperthermia combined with
four drugs
In 2005 we reported the cytotoxicity results of MMC, epirubi-
cin, gemcitabine and EO9 with or without hyperthermia in
four human bladder cancer cell lines (RT4, RT112, 253J and
T24) [81]. MMC is an antibiotic antitumour agent (molecular
weight (MW) 334 g/mol) that interacts with DNA. Cytotoxicity
is a direct result of DNA damage. MMC is the most frequently
used intravesical chemotherapeutic agent. Epirubicin is also a
frequently used agent in NMIBC. It is an analogue of the anti-
biotic antitumour agent doxorubicin (MW 544 g/mol). It binds
to DNA and inhibits nucleic acid synthesis and function. An
intravesically less frequently used drug is gemcitabine, a
deoxycytidine analogue (MW 300 g/mol). After intracellular
activation, the active metabolite is incorporated in the DNA
and results in DNA synthesis inhibition. The fourth agent
studied, EO9, is a bio-reductive alkylating indoloquinone (MW
288 g/mol). The activity of EO9 is presumably related to the
presence of DT-diaphorase enzyme in tumour tissue. This bio-
reductive drug showed good activity in vitro but failed when
given intravenously. The reason for this poor efficacy in vivo
is the rapid clearance from the blood stream. However, this is
of no relevance when used intravesically [82].
In our preclinical study, cells were treated for 60min with
increasing concentrations of the four chemotherapeutic
agents mentioned at 37 or 43 C. Cell survival was deter-
mined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-
bromide (MTT) assay. An inverse relation between cell
proliferation and drug concentrations was demonstrated. EO9
proved to be the most potent agent at both temperatures
(Figure 3). In this experiment hyperthermia alone did not
decrease cell proliferation. However, a synergistic effect of
hyperthermia on decreased cell proliferation was demon-
strated in all cell lines and chemotherapeutic agents used,
although each reached a maximum at a different drug con-
centration (Figure 4). The extent of inhibition was different
between the drugs. The highest level of synergism was seen
in cells treated with epirubicin, and this occurred at lower
drug concentrations. One of the explanations for increased
effect was a higher uptake of the drugs. A counterargument
is the limited effect on cell death shown in gemcitabine, a
drug with a much lower molecular weight than epirubicin.
A more plausible explanation for the increased effect is a
drug-specific activation under hyperthermic conditions.
Summary and conclusions
The remarkable success of intravesical MMC with hyperther-
mia in the treatment of NMIBC lends strong rationale for
moving toward making this therapy a standard of care.
However, the mechanisms underlying the success of this
combination therapy are only partially understood. We have
provided some clues as to what may be in play. More work
needs to be done to investigate mechanisms that lead to
enhanced antitumour effect when combining hyperthermia
with agents that can be used for intravesical treatment.
As a final point, there have been several clinical reports
using MMC and hyperthermia to treat patients whose
tumours have recurred after BCG therapy.[2]. It is curious,
however, that we were unable to identify any reports testing
whether hyperthermia augments the efficacy of BCG. Since
the mechanism underlying efficacy of BCG is thought to be
immunological, one might believe hyperthermia with BCG
would prove beneficial. There is strong evidence that heat
shock proteins play an important role in the efficacy of BCG
[83]. Hyperthermia increases the expression of heat shock
proteins and enhances antigen presentation by dendritic cells
[84,85]. Via a range of effects, hyperthermia boosts the
immune system to increase antitumour efficacy [86–91].
These effects may extend to tumour-bearing areas that are
not effectively heated, via abscopal immune mediated
effects [92].
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